Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Olanzapine transfer by human placenta.

S Schenker1, Y Yang, E Mattiuz

  • 1Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7878, USA.

Clinical and Experimental Pharmacology & Physiology
|September 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans.

Drug metabolism and disposition: the biological fate of chemicals·1998
Same author

Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.

Drug metabolism and disposition: the biological fate of chemicals·1997
Same author

Disposition and biotransformation of the antipsychotic agent olanzapine in humans.

Drug metabolism and disposition: the biological fate of chemicals·1997
Same author

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.

Blood·1995
Same author

Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes.

The Journal of pharmacology and experimental therapeutics·1995
Same author

Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney.

Laboratory investigation; a journal of technical methods and pathology·1995

This study investigated olanzapine transfer across the placenta. Olanzapine and its glucuronide metabolite cross the placenta, influenced by albumin binding, with no oxidative metabolites detected.

Area of Science:

  • Pharmacology
  • Obstetrics
  • Developmental Toxicology

Background:

  • Olanzapine is an effective antipsychotic for schizophrenia treatment.
  • Understanding its transplacental transport is crucial for managing pregnant patients.
  • Human placental transfer data for olanzapine is limited.

Purpose of the Study:

  • To assess the extent and characteristics of human transplacental olanzapine transport.
  • To identify potential metabolites transferred across the placenta.
  • To evaluate the role of albumin binding in olanzapine placental transfer.

Main Methods:

  • Utilized a single-cotyledon, normal-term human placenta perfusion system.
  • Quantified the transfer of radiolabeled olanzapine from maternal to fetal compartments over 4 hours.

Related Experiment Videos

  • Analyzed for the presence of olanzapine metabolites in placental perfusate.

    • Main Results:

    • 5-14% of maternal olanzapine transferred to the fetal compartment within 4 hours.
    • Albumin binding significantly influences olanzapine placental transport.
    • Approximately 17% of olanzapine was converted to its glucuronide metabolite, which transferred slower than the parent drug; no oxidative metabolites were detected.

    Conclusions:

    • Olanzapine crosses the human placenta, with transfer influenced by maternal protein binding.
    • The primary metabolite, olanzapine glucuronide, is also transferred transplacentally.
    • Lack of oxidative metabolites suggests limited placental metabolism of olanzapine.